Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medipost Accelerates Global Push For Lead Stem Cell Therapy

ASEAN, Japan On Near-Term Radar

Executive Summary

South Korean stem cell therapy company Medipost is speeding up the entry of flagship product Cartistem into global markets, with an initial focus on ASEAN countries and Japan and helped by regulators' allowance of early local trials to be waived on the back of strong Korean data.

You may also be interested in...



IVI Warns Of Dire Consequences From COVID-19 Vaccine Inequity

The International Vaccine Institute’s director general warns about COVID-19 vaccine distribution inequalities and its serious consequences, arguing the case for increased global coordination and responsibility for action to improve the situation.

Coronavirus Update: Sotrovimab Filed For EUA In Japan

GSK could soon see an approval in Japan for its antibody therapy following a filing for emergency use, while South Korea looks to build its mRNA vaccine capabilities through a new consortium. 

Genome & Co. Bets On Rosy Microbiome Outlook

Korean bioventure Genome & Co. is accelerating growth by acquiring US microbiome CDMO List Labs, following on from its purchase of US microbiome therapeutics firm Scioto last year. With its microbiome pipeline reaching milestones as planned, Genome appears on track for its goal of becoming a fully integrated global biopharma concern.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel